Q1 2021 Biosyent Inc Earnings Call Transcript
© -
Hello and welcome to the BioSyent Inc. Q1 2021 Results Presentation. My name is René Goehrum, and I'm the President and CEO of the company.
Start today's presentation with a look at our revenue, EBITDA and net income after tax for the recently ended quarter March 31, 2021. Overall, I'd like to say that the Canadian Pharmaceutical business continues to perform well, and we had a significant contribution from our FeraMAX international sales. And in tandem, together with a small uptick from our Legacy Business, they came together to give us our best first quarter ever.
So the first quarter of 2021 was our 43rd consecutive profitable quarter. And what's interesting here is, though, Canadian pharma up modestly at plus 5%, that compares to a year ago where our pharmaceutical business was up 39% in Canada. So I'll take you back to the first wave of COVID. In March of 2020, we had a significant amount of trade and hospital loading kind of semi panic buying that resulted in a very sharp increase in sales in March.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
